Drug-Ultrasound Combination Therapy
Glioblastoma (GBM), newly diagnosed
Phase 2bActively enrolling patients in a pivotal trial
Key Facts
Indication
Glioblastoma (GBM), newly diagnosed
Phase
Phase 2b
Status
Actively enrolling patients in a pivotal trial
Company
About Alpheus Medical
Alpheus Medical is pioneering a drug-ultrasound combination therapy designed to treat aggressive brain cancers like glioblastoma without invasive surgery. Their investigational approach leverages an FDA-approved tumor-targeting drug, which is activated non-invasively by a proprietary ultrasound system to create localized reactive oxygen species and stimulate an immune response. The company is advancing this therapy through a 505(b)(2) regulatory pathway and is currently enrolling patients in a pivotal Phase 2b trial, supported by early clinical data showing a favorable safety profile and encouraging biological activity.
View full company profile